J Breast Cancer.  2006 Sep;9(3):214-229. 10.4048/jbc.2006.9.3.214.

Survival Analysis of Korean Breast Cancer Patients Diagnosed between 1993 and 2002 in Korea: A Nationwide Study of the Cancer Registry

• The Korean Breast Cancer Society

• KMID: 2286652
• DOI: http://doi.org/10.4048/jbc.2006.9.3.214

Abstract

PURPOSE
Breast cancer has been the most prevalent cancer among Korean women since 2001, yet the nationwide survival data for cancer patients has not been examined. The purpose of the present study is to analyze the survival rate of breast cancer patients in Korea using the nationwide data in the cancer registry.
METHODS
The Korean Breast Cancer Society (KBCS) has been collaborating with the Korean Central Cancer Registry (KCCR) to improve the completeness and validity of the breast cancer registry and the mortality data. Data from 1993 to 2002 from KBCS? on-line registry and the KCCR were merged, and a total of 49,174 patients were included for survival analysis.
RESULTS
The five-year observed survival rate and the relative survival rate were 81.2 and 83.2%, respectively, for all patients (80.3 and 82.3%, respectively, for the patients with invasive cancer). The five-year survival rates increased steadily from 1993 to 2002; during the period 1993-1997, the 5-year survival rate was 77.6%, and it was 82.6% during the period 1998-2002, representing an increase of 5%. Both early detection and progress in treatment might have contributed to the increased survival rates. The survival rates are highly dependent on the stage at the time of diagnosis. The five-year observed survival rates were 99.0% for stage 0, 95.6% for stage I, 88.6% for stage II, 64.2% for stage III, and 28.2% for stage IV. No difference in survival according to gender was observed. Patients younger than 35 years of age at diagnosis had a lower rate of survival compared with the older patients. The survival rates of the breast-conserving surgery group was better than that of the mastectomy group; this result was associated with findings that the breast-conserving surgery group had a greater proportion of early cancers and patients with a positive estrogen receptor status and a smaller proportion patients with c-erbB2 overexpression compared with the mastectomy group. The breast-conserving surgery group had smaller tumor sizes and fewer lymph node metastases than that of the mastectomy group in the same stage. The survival rates of invasive cancer with predominant intraductal carcinoma, mucinous carcinoma, medullary carcinoma, and papillary carcinoma were more favorable, whereas inflammatory carcinoma showed poorer survival compared with that of the invasive NOS type. The survival rate of hormone receptor-positive patients was more favorable than that of hormone receptor-negative patients.
CONCLUSION
The present study calculated the nationwide survival rates of Korean breast cancer patients for the first time. The survival rates of Korean breast cancer patients were similar to those of the United States, Europe, and Japan, suggesting the improvement in treatment as well as early detection of breast cancer. Further analysis of the long-term survival and a nationwide collaborative study should be performed to estimate the survival trend of Korean breast cancer patients.

Keyword

Breast Cancer; Survival rate; Stage; Korean; Nationwide

MeSH Terms

Adenocarcinoma, Mucinous
Breast Neoplasms*
Breast*
Carcinoma, Intraductal, Noninfiltrating
Carcinoma, Medullary
Carcinoma, Papillary
Diagnosis
Estrogens
Europe
Female
Humans
Japan
Korea*
Lymph Nodes
Mastectomy
Mastectomy, Segmental
Mortality
Neoplasm Metastasis
Survival Analysis*
Survival Rate
United States
Estrogens

Reference

1. Korea Central Cancer Registry. 2002 Annual report of the Korea Central Cancer Registry. 2003. Gwacheon: Ministry of Health and Welfare, Republic of Korea.

2. The Korean Breast Cancer Study Group. Korean breast cancer data of 1996. J Koeran Surg Soc. 1998. 55:621–635.

3. The Korean Breast Cancer Society. Clinical characteristics of Korean breast cancer patients in 1998. J Korean Med Sci. 2000. 15:569–579.

4. Ahn SH. Korean Breast Cancer Society. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg. 2004. 139:27–30.

5. The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2002 The Korean Breast Cancer Society. J Korean Breast Cancer Soc. 2004. 7:72–83.

6. Choi YH, Kim YJ, Noh DY, Yoo KY. Prediction of future occurrence and probability of developing breast cancer over lifespan in Korean women. J Breast Cancer. 2005. 8:80–85.

7. Son BH, Kwak BS, Kim JK, Kim HJ, Hong SJ, Lee JS, et al. Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg. 2006. 141:155–160.

8. Ahn SH, Yoo KY. Korean Breast Cancer Society. Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996-2004. Breast Cancer Res Treat. 2006. 99:209–214.

9. The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2004 using Breast Cancer Registry Program. J Breast Cancer. 2006. 9:151–161.

10. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A Statistical methodology. National Cancer Inst Monogr. 1961. 6:101–121.

11. Dickman P. Population-based cancer survival analysis. last accessed Apri,2003. Available at: http://pauldickman.com/teaching/toronto2002/index.html.

12. Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patient survival. Eur J Cancer. 2002. 38:690–695.

13. On-line Korean Breast Cancer Registration Program. The Korean Breast Cancer Society. Available at: http://breast.novamd.co.kr.

14. Kim JS, Noh DY, Yoon YK, Oh SK, Cheo KJ. Analysis of postoperative survival and prognostic factors in breast cancer. J Korean Surg Soc. 1998. 54:640–648.

15. Kang SH, Chung KY, Kim YS. Analysis of survival rate and prognostic factors of 989 patients with breast cancer. J Korean Surg Soc. 2004. 66:454–461.

16. Report of survival rate of the cancer patients of 1995. Korean National Cancer Registry Program. Available at: http://www.ncc.re.kr.

17. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2003. 2006. Bethesda, MD: National Cancer Institute; http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site.

18. Bland KI, Menck HR, Scott-Conner CEH, Morrow M, Winchester DJ, Winchester DP. The National Cancer Data Base 10-Year Survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998. 83:1262–1273.

19. Sant M, Aareleid T, Berrino F, Lasota MB, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 results and commentary. Ann Oncol. 2003. 14:61–118.

20. Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003. 106:416–422.

21. Cancer Statistics in Japan 2005. National Cancer Center. last update: 2005/12/28. Available at: http://www.ncc.go.jp/en/statistics/index.html.

22. Yeole BB, Kumar AVR, Kurkure A, Sunny L. Population-based survival from cancer of breast, cervix and ovary in women in Mumbai, India. Asian Pac J Cancer Prev. 2004. 5:308–315.

23. Sankaranarayanan R, Black RJ, Parkin DM. Cancer survival in developing countries. IARC Scientific Publication No-145. 1998. Lyon: International Agency for Research on Cancer.

24. Eaker S, Dickman PW, Hellström V, Zack MM, Ahlgren J, Holmberg L, et al. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev. 2005. 14:2914–2918.

25. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, et al. Breast carcinoma survival in Europe and the United States. Cancer. 2004. 100:715–722.

26. Early Breast Cancer Trialist's Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005. 365:1687–1717.

27. Brenner H, Stegmaier C, Ziegler H. Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol. 2005. 16:981–986.

28. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: The M.D. Anderson Cancer Center experience. Cancer. 2001. 92:2523–2528.

29. Love RR, Duc NB, Dinh NV, Quy TT, Xin Y, Havighurst TC. Young age as an adverse prognostic factor in premenopausal women with operable breast cancer. Clin Breast Cancer. 2002. 2:294–298.

30. Han W, Kim SW, Pak IA, Kang D, Kim SW, Young YK, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004. 4:82.

31. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002. 347:1233–1241.

32. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002. 1227–1232.